Biotech
Zymergen
Zymergen raises $575M Series D at $3.2B valuation
$575M
Total Raised
Series D
Latest Round
2013
Founded
800+
Employees
5980 Horton Street, Emeryville, CA 94608
1 min read
Quick Facts
Valuation
$3.2B
Latest Round Size
$575M
Latest Round Date
February 2024
Zymergen: Series D Funding Round
Zymergen has successfully raised $575M in Series D funding, reaching a valuation of $3.2B.
Company Overview
Bio-based materials manufacturing
Funding Details
The Series D round was led by SoftBank Vision Fund, with participation from DCVC, True Ventures, Data Collective, Two Sigma Ventures.
Company Information
- Headquarters: 5980 Horton Street, Emeryville, CA 94608
- Founded: 2013
- Employees: 800+
- Category: Biotech
Investment
Zymergen plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series D
- DCVC: Verified investor in Series D
- True Ventures: Verified investor in Series D
- Data Collective: Verified investor in Series D
- Two Sigma Ventures: Verified investor in Series D
Key Investors
SoftBank Vision Fund
Lead Investor
Verified investor in Series D
DCVC
Investor
Verified investor in Series D
True Ventures
Investor
Verified investor in Series D
Data Collective
Investor
Verified investor in Series D
Two Sigma Ventures
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M